ArticleScientific reports2025
Investigation of key ferroptosis-associated genes and potential therapeutic drugs for asthma based on machine learning and regression models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Improving machine-learning development in allergology: bridging the gap between open-access and cohort-based databases.Current opinion in allergy and clinical immunology · 2026Review
- Polydopamine-polyethylene glycol-liproxstatin-1 nanoparticles inhibit ferroptosis for enhanced treatment of neutrophilic asthma.Frontiers in pharmacology · 2026Article
- Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling.Frontiers in immunology · 2026Review
- Oxidative stress driven airway mesenchymal reprogramming in asthma: mechanistic insights and evidence from botanical drug formulations.Frontiers in pharmacology · 2026Review
- Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bronchial asthma is a complex and heterogeneous disease, with ferroptosis, a form of non-apoptotic cell death, contributing to its pathogenesis by inducing airway epithelial damage, inflammatory infiltration, and airway remodeling. Investigating ferroptosis-related characteristic genes and potential therapeutic compounds may enhance asthma management. This study employed differential analysis and machine learning to identify ferroptosis-related characteristic genes in asthma using the GSE179156 dataset and FerrDb V2 database. Immune infiltration analysis explored the associations between these genes and immune cells, while potential small-molecule drugs were screened through the Connectivity Map (CMap) database and evaluated via molecular docking and molecular dynamics simulations. Two ferroptosis-related characteristic genes, AGPS and APELA, were identified, with AGPS upregulated and APELA downregulated in asthma, both significantly correlated with various immune cells. A diagnostic model based on these genes demonstrated high predictive accuracy. Additionally, KU-55933 was identified as a potential small-molecule inhibitor of AGPS, with stable binding confirmed through computational simulations. These findings emphasize the role of ferroptosis-related genes in asthma and propose promising therapeutic candidates, providing novel insights into its diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.